$11.03
+0.69 (+6.67%)
Open$10.47
Previous Close$10.34
Day High$11.36
Day Low$10.23
52W High$31.00
52W Low$5.00
Volume—
Avg Volume14.0K
Market Cap19.34M
P/E Ratio—
EPS$-1.69
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+20.3% upside
Current
$11.03
$11.03
Target
$13.27
$13.27
$11.80
$13.27 avg
$20.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.74M | 18.13M | 17.61M |
| Net Income | 675.0K | 507.1K | 519.2K |
| Profit Margin | 3.4% | 2.8% | 3.0% |
| EBITDA | 1.03M | 911.5K | 901.4K |
| Free Cash Flow | 725.0K | 739.6K | 699.1K |
| Rev Growth | -5.2% | +2.0% | -8.0% |
| Debt/Equity | 1.19 | 0.81 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |